Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board - Seite 2

Scott Dehm, Ph.D. is Professor and Apogee Enterprises Chair in Cancer Research, Department of Laboratory Medicine and Pathology at the University Minnesota, Minneapolis. Dr. Dehm’s research laboratory focuses on the role of the androgen receptor (AR) and alterations in AR signaling in prostate cancer development and progression, studying the changes that occur in the AR in response to drug therapies to understand the mechanisms underlying the progression to therapy-resistant disease. His work has revealed new ways in which cancer cells can re-activate the androgen/AR pathway. Dr. Dehm completed a BS and Ph.D. in Biochemistry at the University of Saskatchewan was a Postdoctoral Fellow at the Mayo Clinic.

Gunnar Kaufmann, Ph.D. is Senior Vice President, Chief Scientific Officer and Head of Open Innovation at Kyowa Kirin, Inc., San Diego. Dr. Kaufmann is the former Chief Scientific Officer of Oncternal Therapeutics, and an Adjunct Assistant Professor at The Scripps Research Institute in the Departments of Chemistry and Immunology and Microbial Science. Dr. Kaufmann played a key role in the preclinical development of ONCT-534. Dr. Kaufmann is an active member of the American Association for Cancer Research, the American Association of Immunologists, the Society for ImmunoTherapy of Cancer, and the American Society for Clinical Oncology. He received his Ph.D. in Biology from The Scripps Research Institute, his Master of Science in Human Biology from the University of Greifswald, Germany, and his Bachelor of Science in Human Biology from The Philipps University, Germany.

Howard Soule, Ph.D. – pro-bono advisor – is Executive Vice President & Chief Science Officer at the Prostate Cancer Foundation, Santa Monica. Dr. Howard Soule leads the Prostate Cancer Foundation (PCF) in funding and accelerating prostate cancer research globally. Dr. Soule is a senior fellow of the Milken Institute, a nonprofit, nonpartisan think tank and is also a member of the Department of Defense Prostate Cancer Research Program Integration Panel. He has also served as program director of research and development at Sanofi Diagnostic Pasteur, vice president of research and development at Corvas International, Inc., and vice president and managing director of CaP CURE: Association for the Cure of Cancer of the Prostate. Dr. Soule received a Ph.D. from Baylor College of Medicine in Virology and Epidemiology and was a Post Doctoral Fellow in Immunology and Vascular Biology at the Scripps Research Institute.